What Is New - Epidemiology
Take a look at our 'What is new' highlights in epidemiology!
May 2023
"Machine learning identifies clusters of longitudinal autoantibody profiles predictive of systemic lupus erythematosus disease outcomes"
Why WIN?
This type of data facilitates the estimation of subject-specific trajectories, particularly when there is a significant level of within-subject or between-subject heterogeneity.
Clustering of SLE patients could influence our decision to treat some "profiles" more aggressively.
Agree / Disagree
Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET
Link to original article: https://ard.bmj.com/content/82/7/927
April 2023
"Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study"
Why WIN?
This study suggest a possible increased risk for non-melanoma skin cancers with JAKi as used in clinical practice for RA and PsA
Screening for NMSC (basal cell and squamous cell carcinoma) might be introduced as routine before and during JAKi therapy in patients with RA or PsA.
Agree / Disagree
Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET
March 2023
" Risk of severe COVID-19 outcomes associated with rheumatoid arthritis and phenotypic subgroups: a retrospective, comparative, multicentre cohort study"
Why WINS?
Polygenic risk scores (PRS) have been utilized as a tool to stratify individuals into different risk groups and they are currently explored for several diseases.
Nirmatrelvir-ritonavir, molnupiravir, remdesivir, or other drug could be given to RA-ILD patients in order to prevent a severe Covid 19 outcome.
Agree / Disagree
Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET
February 2023
"Influence of active versus placebo control on treatment responses in randomized controlled trials in rheumatoid arthritis"
Why WINS?
There is a secular trend in RA clinical trials from purely placebo-controlled, towards more active-controlled trials. This study shows that ACR response rates are significantly lower in placebo-controlled, compared to active-controlled studies. Efficacy results of active-controlled and placebo-controlled studies may therefore not be directly comparable, and treatment effectiveness in placebo-controlled studies may be conservative compared to the clinical setting, in which patients will expect active drug treatment.
Does this study influence your expectations of drug effects in clinical practice?
Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET
Jan 2023
" Interactions Between Genetic Risk and Diet Influencing Risk of Incident Female Gout: Discovery and Replication Analysis of Four Prospective Cohorts "
Why WINS?
Gout is the most common type of inflammatory arthritis in developed countries and has become increasingly frequent in other parts of the world, with a disproportionate increase in women over the past three decades. This study shows an interaction between genetic predisposition and diet in women, with nearly half of the excess risk attributable to this gene-diet interaction.
Interactive question
Do you think the rise in incidence of gout in women can be reversed by a healthier dietary pattern?
Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET
December 2022
" Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study "
Why WINS?
Patients with SLE have a two to five times increased risk of mortality compared with age- and gender-matched individuals in the general population. This study validates LLDAS as a treat-to-target endpoint that reduces the risk of mortality. Only glucocorticoid free remission further reduces this risk.
Interactive question
What do you think is the best target in a treat-to-target strategy in SLE ?
1. low disease activity
2. Remission
3. Glucocorticoid free remission
Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET
November 2022
"SARS-CoV-2 Omicron escapes mRNA vaccine boosterinduced antibody neutralisation in patients with autoimmune rheumatic diseases: an observational cohort study"
Why WIN?
This study investigates whether COVID-19 vaccines can elicit cross-reactive antibody responses against the Omicron variant in patients with autoimmune rheumatic diseases (ARDs).
Interactive question
Do you think patients with autoimmune rheumatic diseases have enough immunogenicity for SARS-CoV-2 Omicron after a booster dose of mRNA vaccine? Yes/No
Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET
October 2022
"Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls"
Why WIN?
A third COVID-19 vaccination is recommended for immunosuppressed patients. However, data on immunogenicity and safety of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases (IMIDs) are sparse and therefore addressed within this clinical trial.
Interactive question
Do you think a third COVID-19 vaccination is safe and efficient for patients with immune mediated inflammatory diseases? Yes/No
Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET
September 2022
"Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study"
Why WIN?
Patients under rituximab have impaired humoral responses after primary vaccination, depending on the number of the detectable peripheral B-cells. This study describes that a fourth vaccine dose is immunogenic in a fraction of rituximab-treated patients.
Interactive question
Do you think a second booster dose for COVID-19 has an additional benefit for patients under rituximab treatment?
Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET
May 2022
"Socio-demographic determinants in the evolution of pain in inflammatory rheumatic diseases: results from ESPOIR and DESIR cohorts"
Why WINS?
Pain is one of the most difficult symptoms to treat in Rheumatology. This study identified several socio-demographic factors (older age, female gender, non-Caucasian ethnicity and a lower educational status) that were associated with a poor pain prognosis.
Interactive question
What is the best way to measure pain in clinical practice (thus not for research purposes)?
- Visual analogue scale
- SF-36 pain scale
- Other (please comment)
Join the discussion on twitter... Share your response with us using the hastag #WhatIsNew and tag us @EMEUNET
April 2022
March 2022
February 2022
December 2021
November 2021
October 2021
Jan 2021
December 2020
Nov 2020
October 2020
Sep 2020
February 2020
Jan 2020
December 2019
Nov 2019
Sep 2019
Aug 2019
July 2019
June 2019
May 2019
April 2019
March 2019
February 2019
Jan 2019
December 2018
Nov 2018
October 2018
Sep 2018
Click here to be directed to the article by Whiting et al (2018).
Aug 2018
Click here to be directed to the article by Tan et al (2018).
July 2018
Click here to be directed to the article by Dmitrienko et al (2018).
June 2018
Click here to be directed to the article by Khalifah et al (2018).
May 2018
Click here to be directed to the article by Lesko et al (2018).
April 2018
Click here to be directed to the article by Kahale et al (2018).
March 2018
Click here to be directed to the article by Turk and Pope (2018).
February 2018
Click here to be directed to the article by Costello et al (2017).
Jan 2018
Click here to be directed to the article by Canestaro et al (2017).